New Testing Prompts New Finding Of NDMA, Cancer Risk In Metformin Products

 
• By Joanne S. Eglovitch

The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks. 

Close up of Metformin prescription bottle with glucometer and testing strip container.
FDA issues new findings about NDMA in metformin. • Source: Shutterstock

More from Manufacturing

More from Compliance